Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism NQO1 inhibitors(Quinone reductase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acidosis, Lactic | Preclinical | South Korea | 01 May 2026 | |
| Leigh Disease | Preclinical | South Korea | 01 May 2026 | |
| MELAS Syndrome | Preclinical | South Korea | 01 May 2026 | |
| MERRF Syndrome | Preclinical | South Korea | 01 May 2026 | |
| Optic Atrophy, Hereditary, Leber | Preclinical | South Korea | 01 May 2026 |





